Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think Dan has imploded with the latest Patent grant.
He knows it's only a matter of time - some Big Pharma makes a play for Venturis.
Zhittya Genesis Medicine announces it has won all lawsuits against CardioVascular BioTherapeutics (CVBT-VT) and the court has ruled that Zhittya owns 100% of its own IP relating to FGF-1. Zhittya is proceeding on using FGF-1 for Therapeutic Angiogenesis for 10 separate medical indications.
Interesting comment, johnnymcgriffen347. I don't know if you've noticed, but such behavior is consistent with Schizophrenic Alcoholic Dementia. If you're right johnnymcgrifffen347, it would suggest that Grant Gordon is suffering from Schizophrenic Alcoholic Dementia (SAD) as well as Alcoholic Impotence (AI).
While I've heard consistent rumors from Venturis sources that Grant was pushing Calvin Wallen to pursue the Alcoholic Impotence indication for Venturis Therapeutics's drug which insiders believe was as much for personal reasons, this suggests that Grant's situation is even more dire than outsiders may have realized. I did some reading, and according to the medical literature, patients who are suffering from Schizophrenic Alcoholic Dementia have usually also reached End-Stage Liver Disease (ESLD). It's apparently pretty rare for someone to have SAD who has not already reached the point of ESLD. And we know what happens to ESLD patients.
Sad!
The claims were probably made by our drunkard Grant Gordon. He is a known fraudster and convicted liar, but judging by how horribly inaccurate his statements are about the clinical trials he might just be in a depressed drunken stupor because he can’t produce children.
THE BIG LIE, Venturis/CVBT version:
I see that we now have the Venturis/CVBT version of The Big Lie. Supporters of Venturis Therapeutics are claiming that the company is currently in two ongoing pivotal clinical trials in two different indications.
THAT IS AN OUTRIGHT LIE.
Venturis/CVBT has not run a single clinical trial since 2007. You can not be running an ongoing pivotal trial in 2021 if you haven't run a single clinical trial since 2007.
Here is my question to those who are making this false claim that there are two ongoing pivotal trials taking place: Would you please indicate the month and year of the most recent patients treated in these so-called "pivotal trials"? And tell us what hospital(s) they were treated in?
Let's see what answers are provided here.
For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157492465
Zhittya Genesis Medicine announces it has won all lawsuits against CardioVascular BioTherapeutics (CVBT-VT) and the court has ruled that Zhittya owns 100% of its own IP relating to FGF-1. Zhittya is proceeding on using FGF-1 for Therapeutic Angiogenesis for 10 separate medical indications.
Zhittya Genesis Medicine announces it has won all lawsuits against CardioVascular BioTherapeutics (CVBT-VT) and the court has ruled that Zhittya owns 100% of its own IP relating to FGF-1. Zhittya is proceeding on using FGF-1 for Therapeutic Angiogenesis for 10 separate medical indications.
Zhittya Genesis Medicine announces it has won all lawsuits against CardioVascular BioTherapeutics (CVBT-VT) and the court has ruled that Zhittya owns 100% of its own IP relating to FGF-1. Zhittya is proceeding on using FGF-1 for Therapeutic Angiogenesis for 10 separate medical indications.
Zhittya Genesis Medicine announces it has won all lawsuits against CardioVascular BioTherapeutics (CVBT-VT) and the court has ruled that Zhittya owns 100% of its own IP relating to FGF-1. Zhittya is proceeding on using FGF-1 for Therapeutic Angiogenesis for 10 separate medical indications.
The introduction says Mr. Gordon is unable to have children and is an alcoholic is that true???
Wow the introduction is pretty convincing on not investing, I’m definitely not putting any more money into this fraud of a company!
Status of CVBT/VT Clinical Trials?
As an outsider it’s hard to triangulate on the true status of CVBT/VT clinical trials.
Let us turn to the tangible with CVBT/VT clinical programs. Absent any official Company news releases from CVBT/VT on the resuming of a clinical trial for coronary heart disease and/or wound healing in diabetic foot or venous stasis ulcers we have nothing but innuendo from this site. Investors Hub recent posts refer to these trials as pivotal (which are either P-2B or P-3) and according to the guidelines of clinicaltrials.gov data base, sponsors are required to update the clinical trials.gov data bases for trials at this stage of development. Some P-1 trials are still likely exempt from posting. It appears that the last clinicaltrials.gov update for all three CVBT/VT clinical programs; peripheral arterial disease (PAD), coronary artery disease (CAD) and wound healing of diabetic and venous stasis ulcers was in November of 2019.
CVBT CAD Trial:
https://clinicaltrials.gov/ct2/show/NCT00117936?term=cvbt&draw=2&rank=4
CVBT Treatment of diabetic or venous stasis ulcers:
https://clinicaltrials.gov/ct2/show/NCT00425178?term=cvbt&draw=2&rank=3
CVBT PAD Trial:
https://clinicaltrials.gov/ct2/show/NCT00424866?term=cvbt&draw=2&rank=2
The wound healing trial is reported to be complete. According to clinicaltrials.gov it was an 8-patient trial and by drug development standards would not be considered pivotal in nature. A new P2/3 wound healing protocol has not been posted to the site. If there is a P-2/3 wound healing trial ongoing in the US and not posted it would be in violation of the clinicaltrials.gov guidelines. Same is true for a P-2 trial in CAD. The US FDA in a recently issued guidance April 28, 2021 (see link below) states they intend taking action against sponsors who do not populate the clinical trials.gov site with the required information in a timely fashion.
https://www.fda.gov/news-events/press-announcements/fda-takes-action-failure-submit-required-clinical-trial-results-information-clinicaltrials.gov
If any new clinical trial(s) is/are under way under CVBT’s sponsorship, then good for CVBT/VT and its shareholders.
If not, when might they begin and what are the gating events associated with the restart?
Also, JohnnyM if you look at the old video that was compiled by shareholders in Singapore you'll see that the reason that Daniel C. Montano is affectionately known as Conman Dan is that he has actually been CONVICTED OF FRAUD. See the section at 4.32 titled "Dan Montano Loots Baraban Securities, Still Owes More Than $1.1m".
I hope you find this useful JM.
DAN MONTANO'S FRAUD CONVICTION
It’s somehow worse. Somehow a significant portion of the introduction is illegible as a result of the incompetence of a drunkard man, whose kids cannot show him how to format text correctly because he is impotent. Someone needs to fix the portion of the intro that was made by JBDC
Odd, I can’t even read the first part of the intro. The formatting is horrible, it looks like it was made by a middle-aged alcoholic. Someone should fix the formatting on it or get their kids to fix it (if they are able to have any).
Now for the truth - REDUX
Conman Dan raised no cash for CVBT (as was). The seed capital & all other raises were done by Grant Gordon, the co-founder & present director of CVBT/VT. Grant Gordon also raised all the cash since 2014 when the shareholders kicked out Conman Dan. 95% of the votes were to the new management team who saved the company on behalf of the shareholders.
VT has lost zero lawsuits to Conman. The conman was awarded $800,000 in back wages via an arbitration case, not a lawsuit, which reduces the award Calvin Wallen won (he was awarded $2.5m against Conman) to a net $1.7m. Mr. Wallen very kindly assigned the award to VT. VT is now going after Conman for payment of the $1.7m.
Shittya was kicked in the teeth by the US FDA when they tried to seek permission to conduct trials in USA. Shittya were forced to go to Mexico to conduct a non-FDA Phase 1 trial. To date Conman's Shittya has treated ZERO patients. VT on the other hand has treated over 300 patients successfully with ZERO side effects. VT is also moving into a Phase 2b/3 trial under the auspices of the FDA. As per previous posts, VT is 5 laps ahead of Shittya in a 6 lap race.
p.s. & yes, Conman is still a bankrupt (BK) 8 years after declaring BK.
You're too funny, JohnnyM.
This is going from the sublime to the ridiculous. Apparently, each moderator can input their own "Edit Intro" section before the actual messages. So you have an "interesting" insert by YOU KNOW WHO which is libelous & a comment by me that is an accurate depiction of VT.
It's crazy stuff!!
Zhittya Genesis Medicine Announces New Clinical Trials, New FGF-1 and New Research and Development
Over the last seven years Zhittya Genesis Medicine has advanced far ahead of any competition. Zhittya Genesis Medicine has started Phase I Clinical Trials in Parkinson's Disease and ALS. Zhittya Genesis Medicine has created a new batch of FGF-1 allowing them to progress through clinical trials, bringing them closer to hopeful approval. Zhittya Genesis Medicine has begun research into other diseases to see if FGF-1 could possibly affect the outcomes of sufferers from diseases such as Autism.
It's no wonder since Dan Montano is the CEO of Zhittya Genesis Medicine.
Zhittya Genesis Medicine CEO, Daniel C. Montano founded Cardiovascular BioTherapeutics. Zhittya Genesis Medicine CEO, Daniel C. Montano, raised all the money when he was CEO of CVBT. Zhittya Genesis Medicine CEO, Daniel C. Montano oversaw all of the clinical trials when he was CEO of CVBT.
Since Dan Montano left, CVBT has done nothing. Since Dan Montano left, CVBT/VT has conducted: NO CLINICAL TRIALS, HAS LOST EVERY LAWSUIT, HAS PRODUCED NO FGF-1, HAS RAISED NO MONEY, HAS MADE NO PRESENTATIONS, AND HAS NEVER SENT OUT ANY CORPORATE INFORMATION.
Seven years without Dan Montano and CVBT/VT has done nothing.
Is the introduction true? Can our company’s savior not produce children????
VT is in its pivotal trial with the US FDA for Diabetic Foot Ulcers (DFU).
Shittya is attempting to start a Phase 1 trial in Mexico WHICH IS NOT FDA SANCTIONED
VT has successfully treated over 300 patients
SHITTYA has treated ZERO patients & is highly unlikely to manage to enroll any patients.
I am so sorry, JohnnyM.
You obviously have some real issues with the guy who saved our company. I wonder why?
I also wonder what it says about Conman Dan when an "alcoholic and impotent Grant Gordon?" kicked the-you-know-what outta Conman Dan and Jacobs?
Imagine if he wasn't "alcoholic and impotent".
Is this the same alcoholic and impotent Grant Gordon?
Now for the truth.
Dan Montano raised no cash for CVBT (as was). The seed capital & all other raises were done by Grant Gordon, the co-founder & present director of CVBT/VT. Grant Gordon also raised all the cash since 2014 when the shareholders kicked out Conman Dan (thanks JBDC, I love that very applicable term for Montano). 95% of the votes were to the new management team who saved the company on behalf of the shareholder.
VT has lost zero lawsuits to Conman. Conman was awarded $800,000 in back wages via an arbitration case, not a lawsuit, which reduces the award Calvin Wallen won (he was awarded $2.5m against Conman) to a net $1.7m. Mr. Wallen very kindly assigned the award to VT. VT is now going after Conman for payment of the $1.7m.
Shittya was kicked in the teeth by the US FDA when they tried to seek permission to conduct trials in USA. Shittya were forced to go to Mexico to conduct a non-FDA Phase 1 trial. To date Conman's Shittya has treated ZERO patients. VT on the other hand has treated over 300 patients successfully with ZERO side effects. VT is also moving into a Phase 2b/3 trial under the auspices of the FDA. As per my previous posts, VT is 5 laps ahead of Shittya in a 6 lap race.
p.s. & yes, Conman is still a bankrupt (BK) 8 years after declaring BK.
Zhittya Genesis Medicine will perform diabetic ulcer trial in Mexico? For a possible approval? That has got to be bad news for us at Venturis:
Zhittya Genesis Medicine Announces New Clinical Trials, New FGF-1 and New Research and Development
Over the last seven years Zhittya Genesis Medicine has advanced far ahead of any competition. Zhittya Genesis Medicine has started Phase I Clinical Trials in Parkinson's Disease and ALS. Zhittya Genesis Medicine has created a new batch of FGF-1 allowing them to progress through clinical trials, bringing them closer to hopeful approval. Zhittya Genesis Medicine has begun research into other diseases to see if FGF-1 could possibly affect the outcomes of sufferers from diseases such as Autism.
It's no wonder since Dan Montano is the CEO of Zhittya Genesis Medicine.
Zhittya Genesis Medicine CEO, Daniel C. Montano founded Cardiovascular BioTherapeutics. Zhittya Genesis Medicine CEO, Daniel C. Montano, raised all the money when he was CEO of CVBT. Zhittya Genesis Medicine CEO, Daniel C. Montano oversaw all of the clinical trials when he was CEO of CVBT.
Since Dan Montano left, CVBT has done nothing. Since Dan Montano left, CVBT/VT has conducted: NO CLINICAL TRIALS, HAS LOST EVERY LAWSUIT, HAS PRODUCED NO FGF-1, HAS RAISED NO MONEY, HAS MADE NO PRESENTATIONS, AND HAS NEVER SENT OUT ANY CORPORATE INFORMATION.
Seven years without Dan Montano and CVBT/VT has done nothing.
I look forward to Zhittya Genesis Medicine soon starting their clinical trial in Parkinson's disease patients. When can we expect a similar announcement from Venturis?
It is interesting. As I understand it from my friend, Conman was offered $15,000 per month for 5 years, keep his stock (19m shares), & no legal case against him. However, due to his hubris & mental fragility he decided to fight it. This resulted in him having to file for bankruptcy* & ending up with no shares in CVBT. It's very sad that mental illness plunged him, his family & a few hangers on into the abyss.
*he still has not been discharged from the bankruptcy almost 8 years later.
Imagine a company so great its more obsessed with it's competition and the CEO's former company than executing on its own business plan.
I'm glad that discussion of the Schizophrenic Alcoholic Dementia possibilities amuses you. You can look forward to lots of amusement to come.
Its the other way round. VT is about to go after Conman Dan for the balance of $1.7m he owes them.
Conman has a history of snatching defeat from the jaws of victory. Watch the 7 minute video of his history. It's frightening how many people/companies he's destroyed due to his hubris
Can Zhittya Genesis Medicine really sue Venturis directors personally? That does not sound good, but I am sure Venturis has insurance to cover that:
Actually, I'm wondering how you could possibly know about the non-existent "debtor exam".
Ooops
Unfortunately, for Dan Montano, VT is now owed $1.7m.
Nothing was ever settled in the $2.5m judgement against Montano.
With the $3bn IPO that SHITTYA is executing this month it will be small potatoes for such a major player as Dan, Dan, the Conman. He'll probably have that in his back pocket.
As always thanks for keeping us amused, JohnnyM.
Daniel C. Montano has initiated a Debtor's Exam against CVBT/VT
Daniel C. Montano has initiated a Debtor's Exam against CVBT/VT, within the next 30 days the shareholders will know that CVBT/VT has no financial viability and is an empty shell of a company.
I fear that Dan Montano will seize all of the assets, including IP, that CVBT has and will sue the CVBT/VT directors for their actions.
Zhittya Genesis Medicine Announces New Clinical Trials, New FGF-1 and New Research and Development
Over the last seven years Zhittya Genesis Medicine has advanced far ahead of any competition. Zhittya Genesis Medicine has started Phase I Clinical Trials in Parkinson's Disease and ALS. Zhittya Genesis Medicine has created a new batch of FGF-1 allowing them to progress through clinical trials, bringing them closer to hopeful approval. Zhittya Genesis Medicine has begun research into other diseases to see if FGF-1 could possibly affect the outcomes of sufferers from diseases such as Autism.
It's no wonder since Dan Montano is the CEO of Zhittya Genesis Medicine.
Zhittya Genesis Medicine CEO, Daniel C. Montano founded Cardiovascular BioTherapeutics. Zhittya Genesis Medicine CEO, Daniel C. Montano, raised all the money when he was CEO of CVBT. Zhittya Genesis Medicine CEO, Daniel C. Montano oversaw all of the clinical trials when he was CEO of CVBT.
Since Dan Montano left, CVBT has done nothing. Since Dan Montano left, CVBT/VT has conducted: NO CLINICAL TRIALS, HAS LOST EVERY LAWSUIT, HAS PRODUCED NO FGF-1, HAS RAISED NO MONEY, HAS MADE NO PRESENTATIONS, AND HAS NEVER SENT OUT ANY CORPORATE INFORMATION.
Seven years without Dan Montano and CVBT/VT has done nothing.
Zhittya Genesis Medicine Announces Daniel C. Montano, its CEO, has a $1 million dollar judgement against CVBT/VT, confirmed by the US Federal Court
Zhittya Genesis Medicine's CEO, Daniel C. Montano, has a judgement for over $1 million dollars, confirmed by the United States Federal Court. Anonymous posters have claimed that CVBT/VT has an offsetting claim. However, Calvin Wallen's claim was settled years ago, and there is NO OFFSET.
Why has there been no announcement from our administration that CVBT/VT lost a lawsuit to Daniel C. Montano?
Why has our administration not announced that Daniel C. Montano stole no IP from CVBT according to the Judge who dismissed the charges?
Why has our administration not disclosed that CVBT/VT has no way of stopping Dan Montano from competing against us?
Why has our administration not announced the possibility of Dan Montano initiating a debtor's exam and seizing all of CVBT/VT's assets?
WHAT VALUE ARE THE CVBT PATENTS TO US IF DAN MONTANO CAN SIEZE THEM TO SETTLE HIS CLAIM?
I understand that Goldman Sachs have pleaded with Conman Dan to allow them to do an IPO in May to raise $3 billion valuing SHITTYA at $120 billion. They especially like SHITTYA because they have no patents, no clinical data, are led by a convicted fraudster* & have run afoul of the US FDA**
What a success story
*Baraban Securities bankruptcy where Conman Dan was convicted of Fraud. See the Worst CEO video. Laments of a Bankrupted, Failed CEO
** The US FDA threw out SHITTYA's IND application for their Phase 1 trial due to dubious figures & claims which is why they are trying to do a trial in Mexico unsanctioned by the FDA.
JBDC, do you think FGF can do anything about paranoia?
LMAO!!!!!!
That is so amusing. Thanks Walhall. Never a dull moment.
Isn't it true that people who have conversations with themselves under multiple different identities are exhibiting texbook symptoms of schizophrenic alcoholic dementia?
Perhaps someone with laser-guided insights could comment on this. And perhaps share any insights he/she may also have on how long it takes for schizophrenic alcoholic dementia to progress to end-stage liver disease. Is it also true that progression occurs more rapidly in patients who are of Northern European descent?
And isn't it true that Venturis Therpeutics/CVBT recently filed a patent on treating schizophrenic alcoholic dementia with its drug?
I'm sure we will hear the details of this in the 2021 shareholders meeting which will be held in May 2021 as required by the company's bylaws. Oh wait...there is no shareholders meeting being held in May 2021, in violation of the company's bylaws AND Calvin Wallen's written promises to the shareholders, FOR THE SECOND YEAR IN A ROW.
For more information:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=157492465
Any more news on Zhittya Genesis Medicine IPO? If they raised mucho dinero in an IPO that would be bad news for Venturis.
Zhittya Genesis Medicine YouTube videos are pretty impressive. I think we should do that.
Good to see you on the board again, Slalom. I've missed your laser guided posts. As a matter of interest have you heard anything about an influx of cash into our company?
If you don't want to post it you can email me at the usual address.
The new IP is, IMHO, blockbuster stuff.
I understand that the following is referred to as projection.
"This is all of what one would expect from an alleged crook (the Grand Poobah here) and his cronies of idiots from the oil and gas industry, who know about as much about biotech as Kim Kardashian does. At least she has real wealth, and actually earned it honestly. Unlike those who shall not be named who have been accused of theft of company assets, theft of investor assets, and fraud more than once in their careers."
Ya reckon......LOL
Filing a patent, yes it could be complete Dan,Dan the Conman aka Cr@p. Having a patent granted by The United States Patent & Trademark Office is completely different. VT now has 11 different patents on it therapeutic programs & 52 pending.
Remind me, how many patents does Shittya have?
[cue the Jeopardy! tune]
Oh, that's correct, ZERO, Nada, Cero, sifr, Nul, Nula, Kore, ????, Zilch!!
I would not buy into the IPO. I believe Montano will suck in many investors to put himself back into the green. As a longtime CVBT stock owner I am out thousands at this point due largely to Montano's mismanagement.
Followers
|
39
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3648
|
Created
|
04/08/05
|
Type
|
Free
|
Moderators |
VENTURIS THERAPEUTICS (formerly Cardiovascular
Biotherapeutics or CVBT) is a dead, zombie company
that hasn't run a single clinical trial in nearly 15
years. Not even one patient (!) has been treated
since 2007. Venturis Therapeutics is insolvent,
illiquid, and is controlled and run by an individual
who was accused by the U.S government of
embezzling $14 million from his previous company.
Venturis' lawyer, Barry Cannaday of Dentons (one
of the largest law firms in the U.S.), withdrew from
representing Venturis in April 2021 because Dentons
is owed over $200,000 by Venturis, and Mr. Cannaday
attested that "there are currently no assets or
revenue streams" to pay Dentons. Yet anonymous
advocates for Venturis (who I personally believe are
the company's desperate leadership) lie about public
facts that are easily verifiable. One of the most
absurd false claims is that there are (allegedly) two
ongoing pivotal clinical trials (see that particular
false claim below). These "clinical trials" exist only
in cyberspace but not in the real world the rest of us
(including Dentons) live in. That said, enjoy the
entertainment that lies below. Hopefully it gives you
some good laughs - that's about all that's left from
this dead, zombie company. Enjoy!
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS (VT) OVERVIEW
VT was almost bankrupted by the original
CEO, Daniel C. Montano, and was rescued by
Calvin Wallen, Grant Gordon and then CFO,
Mickael Flaa.
VT had almost $40,000,000 in debt & was
effectively insolvent. The board of directors
who replaced the Dan Montano cronies
rehabilitated VT so that today the company has
almost zero debt and an comprehensive patent
portfolio. Under the disasterous management
of Dan Montano, the company had zero
patents.
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage
biopharmaceutical company advancing novel
therapeutics to address diseases such as
diabetic wounds, severe ischemic heart disease
and
peripheral artery disease. Our pre-clinical
therapeutic programs include erectile
dysfunction,
infarct stroke, degenerative disk disease and
Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on
targeted delivery of next generation
molecules which will improve the quality of life
for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast
Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when
administered to ischemic organs and
tissues. These anatomical targets are shown in
our pipeline section of the website.
www.vt.care
VENTURIS THERAPEUTICS OVERVIEW
Our Approach in Science and Technology:
Venturis Therapeutics, Inc. is a clinical stage biopharmaceutical company advancing novel
therapeutics to address diseases such as diabetic wounds, severe ischemic heart disease and
peripheral artery disease. Our pre-clinical therapeutic programs include erectile dysfunction,
infarct stroke, degenerative disk disease and Parkinson’s Disease.
Venturis Therapeutics, Inc. is focused on targeted delivery of next generation
molecules which will improve the quality of life for those suffering from vascular dysfunction.
We employ human proteins from the Fibroblast Growth Factor family. Our lead candidate
stimulates the growth of new blood vessels when administered to ischemic organs and
tissues. These anatomical targets are shown in our pipeline section.
vt.care
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Venturis Therapeutics (VT) is
a biotechnology company based
in Dallas, Texas. VT has pivotal trials
ongoing in Ischemic Heart Disease &
Diabetic Foot Ulcers.
VT has a comprehensive patent
portfolio protecting its therapeutic
programs.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |